New guidance on the conduct of clinical trials during public health emergencies in the EU
Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 54, Status: Authorised
Agenda - Ad hoc Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 5 March 2026
Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 5 March 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 5 March 2026, 15:15 (CET) to 5 March 2026, 16:15 (CET)
Human medicines European public assessment report (EPAR): Otezla, apremilast, Date of authorisation: 15/01/2015, Revision: 25, Status: Authorised
We are pleased to announce the launch of the EFIM Clinical Research Grants 2026 programme.
The EFIM Clinical Research Grant 2026 aims to support innovative and collaborative clinical research projects in Internal Medicine, strengthening research capacity and fostering cooperation between EFIM Ordinary and Associate National Societies.
The grants are designed to encourage innovative research that advances patient care, promotes evidence-based practice, and strengthens the academic community within Internal Medicine.
List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (PSURs)
EMA/PE/0000230484
EMA/PE/0000227908
Opinion/decision on a Paediatric investigation plan (PIP): Voydeya, danicopan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Renal and urinary disorders, PIP number: EMA/PE/0000227558